Joseph Oberholtzer

LEAH Labs is building living therapies for pets and their people.

Lento Bio was formed in 2022 in partnership with Ichor Life Sciences, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage.

Astrocyte Pharmaceuticals is a clinical-stage drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients. Astrocyte is committed to proving the neuro- and cerebroprotective benefits of enhanced mitochondrial energy production in astrocytes, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

The Extracellular Matrix (ECM) - the scaffolding material that organizes cells into tissues and organs - is a proactive participant in chronic disorders enabling continued inflammation, fibrosis and ischemia. Spun off from Brown University in 2022, XM Therapeutics is developing a platform technology to directly modulate the dysfunctional ECM to improve tissue function and enable organ repair. We generate injectable, acellular designer ECM Particles sourced from human 3D cell cultures. Our initial focus is on cardiovascular and pulmonary indications with significant additional potential in other diseases. We are a Providence, RI - based seed stage start-up with a clear mission: to improve the health status of patients with chronic disorders by modulating and repairing the dysfunctional Extracellular Matrix.

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.

We are a cancer therapeutics company with a mission to improve efficacy, reduce toxicity and increase treatment affordability of cancer drugs. We are an experienced team in cancer drug discovery and development. Team members have invented and developed drugs that are approved for cancer treatment. Our approach to eradicating cancer is distinct from the current standard of care. Current approaches involve single agent single action drugs that either inhibit cancer cell growth or inhibit immunosuppression, and hence, they are ineffective. These drugs are combined in a bid to improve efficacy. But combination leads to toxicity, poor efficacy, and high cost. We are developing single agent dual action treatments inhibiting both cancer growth and immunosuppression. We are not targeting the immune checkpoint axis. Our approach will be effective for cancer patients that failed immune checkpoint treatments due to resistance or low expression of PD1, PDL1, CTLA4 etc..

Founded by myeloma research pioneer and oncologist, James R. Berenson, M.D., OncoTracker provides proprietary serum BCMA testing, patient-derived xenografts (PDX), access to an ongoing extensive library of clinically characterized biospecimens, and consultative services, to help pharmaceutical and biotechnology companies develop and evaluate new drugs. OncoTracker’s facilities, including a state-of-the-art GLP laboratory and biorepository, are ideally suited to support drug development and clinical studies worldwide. Located in West Hollywood, CA, the company has provided critical testing, biospecimens, patient-derived xenografts and consultative guidance to research institutions, pharmaceutical companies and contract research organizations around the world to further the development of BCMA-directed drugs. OncoTracker welcomes the opportunity to discuss how its unique testing services and programs may help your drug development needs.

Our technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development. We are comprised of a talented, diversely-skilled team, working together towards the mission of helping bring new therapies to patients with epigenetically-driven diseases.

Character Biosciences is a precision medicine company transforming drug development for progressive, polygenic diseases, beginning with ophthalmology. Our mission is to identify the genetic and molecular drivers of disease progression so we can develop targeted therapies for patients who urgently need them. Weve built one of the most comprehensive resources in age-related eye diseases by partnering with over 150 ophthalmology clinics to integrate genetics with longitudinal clinical and imaging data. This deep phenotyping approach enables us to reclassify complex diseases like age-related macular degeneration (AMD) into genetically defined subtypes, unlocking novel therapeutic targets and optimizing patient selection for clinical trials. Character Bio’s AI-powered platform combines genomics, multi-modal data, and machine learning to discover and develop therapies that are more precise and more effective. Our lead programs, CTX114 and CTX203, are advancing toward clinical trials and are designed to slow or prevent vision loss in AMD patients. We are committed to delivering a new generation of precision medicines to treat and ultimately cure age-related blindness.

LEAH Labs is building living therapies for pets and their people.

Lento Bio was formed in 2022 in partnership with Ichor Life Sciences, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage.

Astrocyte Pharmaceuticals is a clinical-stage drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients. Astrocyte is committed to proving the neuro- and cerebroprotective benefits of enhanced mitochondrial energy production in astrocytes, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

Life Detection Technologies is leveraging our evolutionary and patented vital sign monitoring technology to eliminate/reduce the severity of COPD "flare ups" - known as exacerbations.

The Extracellular Matrix (ECM) - the scaffolding material that organizes cells into tissues and organs - is a proactive participant in chronic disorders enabling continued inflammation, fibrosis and ischemia. Spun off from Brown University in 2022, XM Therapeutics is developing a platform technology to directly modulate the dysfunctional ECM to improve tissue function and enable organ repair. We generate injectable, acellular designer ECM Particles sourced from human 3D cell cultures. Our initial focus is on cardiovascular and pulmonary indications with significant additional potential in other diseases. We are a Providence, RI - based seed stage start-up with a clear mission: to improve the health status of patients with chronic disorders by modulating and repairing the dysfunctional Extracellular Matrix.